Clinical trials: MRD-positive
ALL, Adult
Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
T-ALL accounts for about 15%-25% of Ph-negative ALL, and its clinical prognosis is worse than B-ALL. The successful application of immunotherapy has brought revolutionary progress to the treatment of ALL.
- Trial name
- T-ALL-2024 (NCT06570915)
- Testing
- Daratumumab Injection
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
MRD, MDD
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children.
- Conditions
- MRD, MDD, Lymphoma, Nonhodgkin, Anaplastic Lymphoma
- Trial name
- NCT03971305
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
ALL, Recurrent, Adult
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
This study is designed to confirm the efficacy, safety, and tolerability of blinatumomab in patients with MRD of B- precursor ALL in complete hematological remission including patients with relapse after SCT.
- Trial name
- NCT03109093
- Testing
- Blinatumomab
- Where
- 22 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Goethe University
3-year Disease-free Survival
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).
- Trial name
- NCT06561620
- Testing
- Befotertinib
- Where
- China
- Volunteers
- 592 people
- Sponsor
- Fudan University
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
PETHEMA-BLIN-01/PET069014 (BLIN-01)
The PETHEMA Spanish group treats patients with high-risk Philadelphia chromosome-negative ALL, aged 18 to 55 years, based on the MRD clearance as assessed by flow cytometry at a centralised evaluation centre.
- Trial name
- NCT03523429
- Testing
- blinatumomab
- Where
- 12 sites in Spain
- Volunteers
- 11 people
- Sponsor
- PETHEMA Foundation
Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
This trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia (B-ALL).
- Trial name
- NCT03913559
- Testing
- Inotuzumab ozogamicin, Methotrexate, Hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- St. Jude Children's Research Hospital
Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
This phase II trial studies how well ABL001 works in treating patients with chronic myeloid leukemia who are on therapy with tyrosine kinase inhibitor.
- Trial name
- NCT04216563
- Testing
- Asciminib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)
This is an open-label, multi-center, randomized, phase III study. It is aimed to firstly evaluate the effectiveness and safety of almonertinib induction therapy in EGFR-mutated patients with unresectable stage III non-small cell…
- Trial name
- APPROACH (NCT04841811)
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Guangdong Association of Clinical Trials
Acute Lymphoblastic Leukemia
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
This investigator-initiated, prospective, single-arm, open-label, single-center clinical study aims to evaluate the efficacy and safety of Inaticabtagene autoleucel (Inati-cel;CNCT19)CD19 CAR-T theraphy in adults B-ALL that are…
- Trial name
- NCT06718244
- Testing
- single dose of Inaticabtagene autoleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Various drugs have been added to different treatment regimens in order to improve the response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that adding Bortezomib to the relapsing regimen…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease
- Trial name
- NCT05137860
- Testing
- Bortezomib
- Where
- Mexico
- Volunteers
- 56 people
- Sponsor
- Hospital General de Mexico
Colon Cancer
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival…
- Trial name
- CLAUDIA (NCT05534087)
- Testing
- mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy
- Where
- 13 sites in South Korea
- Volunteers
- 236 people
- Sponsor
- Seoul National University Hospital
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03624530
- Testing
- Tyrosine kinase inhibitor (TKIs)
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Nanfang Hospital, Southern Medical University
AML, Adult
MRD-positive AML Clinical Study
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the…
- Trial name
- NCT07131059
- Testing
- Ivosidenib, Gilteritinib, Venetoclax
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Leukemia, Acute Myeloid Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further…
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma
- Trial name
- NCT03314974
- Testing
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
This investigator-initiated, prospective, single-arm, multicenter clinical trial aims to evaluate the efficacy and safety of BEBT-908 (a HDAC/PI3Kα inhibitor provided by BeBetter Med Inc ,Guangzhou, China) combined with…
- Trial name
- NCT07301138
- Testing
- BEBT-908, Cyclophosphamide, Vincristine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Ruijin Hospital
Multiple Myeloma
Short Course Daratumumab in Patients With Multiple Myeloma
The purpose of this study is to test the safety of short course Daratumumab in combination with lenalidomide and to find out what effects, if any, short course Daratumumab in combination with lenalidomide has on people and their…
- Trial name
- NCT03490344
- Testing
- Daratumumab, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Immunotherapy
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
This trial is a non-blinded, single-center, open-label, single-arm clinical study to evaluate a full-course immunotherapy regimen in patients with B-cell acute lymphoblastic leukemia (B-ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab Ozogamicin
- Trial name
- NCT06985485
- Testing
- Blinatumomab and Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
A study on the effectiveness and safety of haploidentical hematopoietic stem cell transplantation in patients with MRD positive CD19+ ALL treated with conditioning regimens containing Blinatumomab
- Trial name
- NCT06125106
- Testing
- Blinatumomab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang University
Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
This is a phase II interventional trial to evaluate if the use of ponatinib, with or without chemotherapy, can induce a molecular remission in MRD-positive patients, in patients in hematologic and extra-hematologic relapse and in…
- Trial name
- NCT04475731
- Testing
- Ponatinib
- Where
- 22 sites in Italy
- Volunteers
- 67 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in…
- Trial name
- NCT04086264
- Testing
- Azacitidine, IMGN632, Venetoclax
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 218 people
- Sponsor
- AbbVie